We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
0
0 active
Approvals
32
Total approvals
Agencies
1
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
FDA
Food and Drug Administration
- Biocon Limited has opened its first FDA-approved manufacturing facility in Cranbury, New Jersey, through its subsidiary Biocon Generics Inc, marking a significant milestone in the company's global expansion strategy. - The company invested over $30 million to establish the state-of-the-art oral solid dosage facility with an annual production capacity of 2 billion tablets after acquiring it from Eywa Pharma Inc. in 2023. - The facility enables Biocon to deliver vertically integrated, high-quality medicines more efficiently to US patients while strengthening supply chain resilience and accelerating global market expansion. - New Jersey Governor Phil Murphy attended the inauguration, highlighting the facility's role in fostering innovation, creating job opportunities, and strengthening the US healthcare ecosystem.
